11 completed, 3 not yet recruiting, 3 recruiting, 3 withdrawn. 24 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 24 | Completed 11, Not yet recruiting 3, Recruiting 3, Withdrawn 3, Active not recruiting 2, Terminated 2 |
| Phase 2 | 8 | Completed 3, Terminated 2, Withdrawn 2, Not yet recruiting 1 |
Follow PTSD: new trials by email Literature Review of PTSD trials Research Report on PTSD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Stimulant Medications in PTSD Placebo, Adderall - Adderall, PTSD | Phase 1 | Not yet recruiting | University of Chicago | 40 | 2026-09-15 | 2026-06-24 |
| Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery Cannabidiol (CBD) only, Placebo only, Delta-9-tetrahydrocannabinol (THC) only - PTSD, Post Traumatic Stress Disorder | Phase 1 / Phase 2 | Not yet recruiting | Leslie Lundahl | 280 | 2026-09-01 | 2026-08-26 |
| Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder Psilocybin - PTSD | Phase 1 | Recruiting | University of New Mexico | 36 | 2026-05-01 | 2026-05-22 |
| Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD Psychedelic - PTSD | Phase 1 | Active not recruiting | Scottsdale Research Institute | 24 | 2026-03-20 | 2026-07-29 |
| Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia PROSOMNIA Sleep Therapy™ (PSTx), Anesthesia-Induced Sleep Therapy, Diprivan (propofol), Astra-Zeneca - Chronic Insomnia, Sleep Deprivation | Phase 1 | Not yet recruiting | Nyree Penn | 100 | 2025-11-01 | 2025-05-28 |
| Feasibility of a Digital Therapeutic for Adults With Posttraumatic Stress Disorder (PTSD) OTX-601 Digital Therapeutic - Version 1, OTX-601 Digital Therapeutic - Version 2, Treatment as Usual (TAU) - PTSD, Post Traumatic Stress Disorder | Phase 1 | Completed | Oui Therapeutics, Inc. | 40 | 2025-06-30 | 2026-07-27 |
| The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective. Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression., Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD, Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder. - Anxiety, Depression | Phase 1 | Completed | Rakitzi, Stavroula | 107 | 2025-06-02 | 2026-08-04 |
| Deep Brain Stimulation for Refractory PTSD Open Label Deep Brain Stimulation, Double blinded Deep Brain Stimulation, Prolonged exposure therapy - PTSD | Phase 1 | Recruiting | Sunnybrook Health Sciences Centre | 20 | 2024-11-01 | 2024-11-26 |
| Open-Label Psilocybin Study in Transdiagnostic Population Psilocybin - Transdiagnostic, Depression - Major Depressive Disorder | Phase 1 | Recruiting | Yale University | 50 | 2024-10-17 | 2026-03-11 |
| First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM) Fluoroethylnormemantine (FENM) - PTSD, Alzheimer Disease | Phase 1 | Withdrawn | ReST Therapeutics | 2024-05-02 | 2024-05-03 | |
| Ultrasonic Neuromodulation for Treatment of PTSD Diadem - PTSD | Phase 1 / Phase 2 | Terminated | University of Utah | 10 | 2024-04-05 | 2025-05-25 |
| Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD Ketamine Hydrochloride - PTSD | Phase 1 / Phase 2 | Withdrawn | University of New Mexico | 2023-12-31 | 2024-03-12 | |
| Group MDMA-therapy for Veterans With PTSD MDMA, Group Therapy - PTSD | Phase 1 / Phase 2 | Completed | Portland VA Research Foundation, Inc | 23 | 2023-10-01 | 2025-06-12 |
| Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder Brexanolone - PTSD, Alcohol Use Disorder | Phase 1 | Active not recruiting | Yale University | 25 | 2023-08-01 | 2025-10-14 |
| Methylphenidate for Ptsd and Stroke Veterans Methylphenidate, Placebo - PTSD, Stroke | Phase 1 / Phase 2 | Completed | VA Office of Research and Development | 20 | 2022-01-14 | 2025-06-22 |
| Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD) Lu AG06466, Placebo - PTSD | Phase 1 | Completed | H. Lundbeck A/S | 35 | 2020-09-30 | 2023-03-24 |
| Clinical Trial Intelligent Biometrics for PTSD - Clinical Trial Therapist Guided Prolonged Exposure with BioWare Device, Record Only Prolonged Exposure with BioWare Device - PTSD | Phase 1 | Completed | Medical University of South Carolina | 40 | 2020-06-08 | 2023-10-31 |
| rTMS for Emotional Difficulties in Verterans Repetitive Transcranial Magnetic Stimulation (rTMS) - Mental Health, Depression | Phase 1 | Completed | VA Office of Research and Development | 21 | 2019-02-01 | 2023-11-09 |
| A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD) Riluzole - PTSD | Phase 1 | Completed | Yale University | 18 | 2014-01-01 | 2020-04-01 |
| Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD) Riluzole, Placebo (for Riluzole) - PTSD | Phase 1 / Phase 2 | Completed | Uniformed Services University of the Health Sciences | 75 | 2013-07-01 | 2021-05-24 |
Showing 20 of 24. Sign in to see all of them.
Stress Disorders, Post-Traumatic (24) · Anxiety Disorders (4) · Depression (4) · Alzheimer Disease (2) · Psychological Well-Being (2) · Acquired Immunodeficiency Syndrome (1) · Alcoholism (1) · Behavior, Addictive (1) · Bipolar Disorder (1) · Brain Diseases (1) · Cancer Pain (1) · Chronobiology Disorders (1) · Combat Disorders (1) · Depressive Disorder, Major (1) · Depressive Disorder, Treatment-Resistant (1)
Mental Disorders (24) · Stress Disorders, Traumatic (24) · Trauma and Stressor Related Disorders (24) · Behavior (5) · Behavioral Symptoms (5) · Central Nervous System Diseases (3) · Nervous System Diseases (3) · Brain Diseases (2) · Chemically-Induced Disorders (2) · Dementia (2) · Mood Disorders (2) · Neurocognitive Disorders (2) · Neurodegenerative Diseases (2) · Personal Satisfaction (2) · Tauopathies (2)
Psilocybin (2) · Riluzole (2) · Adderall (1) · Cannabidiol (1) · Doxazosin (1) · Dronabinol (1) · Electroencephalography (1) · Hallucinogens (1) · Ketamine (1) · Methylphenidate (1) · N-Methyl-3,4-methylenedioxyamphetamine (1) · Perindopril (1) · Propofol (1) · Psychotherapy, Group (1) · Single Person (1)
VA Office of Research and Development (3) · Yale University (3) · University of New Mexico (2) · Baylor College of Medicine (1) · H. Lundbeck A/S (1) · Leslie Lundahl (1) · Medical University of South Carolina (1) · Nyree Penn (1) · Oui Therapeutics, Inc. (1) · Portland VA Research Foundation, Inc (1) · Rakitzi, Stavroula (1) · ReST Therapeutics (1) · Scottsdale Research Institute (1) · Stanford University (1) · Sunnybrook Health Sciences Centre (1)
United States (21) · Belgium (1) · Canada (1) · Greece (1)
Alicia Heapy, Ph.D. (1) · Benjamin Kelmendi, MD (1) · Chadi Abdallah, MD (1) · Chen Lin, MD (1) · Cheryl Gore-Felton, PhD (1) · David M Benedek, MD (1) · Dr. Polyxeni Georgila, M. D. (1) · Dr. Stavroula Rakitzi, PhD (1) · Elisabeth Wilde, PhD (1) · Ellen Teng, PhD (1) · Gabrielle Agin-Liebes, PhD (1) · Jan Kubanek, PhD (1) · Lisa M. McTeague, PhD (1) · MacKenzie R Peltier, PhD (1)
PMID 27249080, PMID 33113596, PMID 36347106, PMID 41947855, PMID 42395285
IK2CX002104 (1), R44MH136888 (1), U54AA027989 (1)